Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of panitumumab with docetaxel and cisplatin as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma
2010-021192-87Phase 2Completed
- Sponsor
- Grupo Gallego de Investigación en Oncología
- Start
- Sep 2010
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab, docetaxel and cisplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Grupo Gallego de Investigación en Oncología. Primary endpoint: Objective response rate. Started Sep 2010; status: completed.
02
Drugs
panitumumabdocetaxelcisplatin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-021192-87.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021192-87.